Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17

1. Ruggenenti P, Remuzzi G: Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 1998, 9:2157–2169.

2. Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999, 341:1127–1133.

3. Agodoa LY: U.S. Renal Data System, USRDS 2001 Annual Data Report. Am J Kidney Dis 2001, 38(Suppl 3): S37–S52.

4. Stephenson JM, Fuller JH,Viberti GC, et al.: EURODIAB IDDM complications study group. Blood pressure, retinopathy, and urinary albumin excretion in IDDM. Diabetologia 1995, 38:599–603.

5. Chihara J,Takebayashi S,Takashi T, et al.: Glomerulonephritis in diabetic patients and its effect on the prognosis. Nephron 1986, 43:45–49.

6. Warram JH, Krolewski AS: Use of the albumin/creatinine ratio in patient care and clinical studies. In The Kidney and Hypertension in Diabetes Mellitus. Edited by Mogensen CE. London: Kluwer Academic Publishers; 1998:85–96

7. Tisher CC, Hostetter TH: Diabetic nephropathy. In Renal Pathology, edn 2. Edited by Tisher CC, Brenner BM. Philadelphia: JB Lippincott; 1994:1387–1412.

8. Parving HH, Hommel E, Mathiesen E, et al.: Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes. Br Med J 1988, 296:156–160.

9. Krolewski AS, Fogarty DG,Warram JH: Hypertension and nephropathy in diabetes mellitus: what is inherited and what is acquired? Diab Res Clin Practice 1998, 39(suppl):S1–S14.

10. Quinn M,Angelico MC, Warram JH, et al.: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996, 39:940–945.

11. Nelson RG, Newman JM, Knowler WC, et al.: Incidence of end stage renal disease in Type 2 (non–insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1988, 31:730–736.

12. Biesenbach G, Grafinger P, Janko O, et al.: Influence of cigarette smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clin Nephrol 1997, 48:146–150.

13. Zatz R, Rentz DB, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925–1930.

14. Brenner B, Mackenzie HS: Nephron mass as risk factor for the progression of renal disease. Kidney Int 1997, 63(Suppl):S124–S127.

15. Giugliano D, Ceriello A, Paolissa G: Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19:257–267.

16. Bierhaus A, Hofmann MA, Ziegler R, et al.: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998, 37:586–600.

17. Vlassara H, Striker LJ,Teichberg S, et al.: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994, 91:11704–11708.

18. Makita Z, Radoff S, Rayfield EJ, et al.: Advanced glycation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836–842.

19. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859–866.

20. Ishii H, Jirousek MR, Koya D, et al.: Ameliorations of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728–731.

21. Hoffman BB, Sharma K, Ziyadeh FN: Potential role of TGF-b in diabetic nephropathy. Min Electrol Metab 1998, 24:190–196.

22. The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.

23. Bakris GL: Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diab Res Clin Prac 1998, 39(Suppl):S35–S42.

24. Wolf G, Ziyadeh FN:The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997, 29:153–163.

25. Slataper R,Vicknair N, Sadler R, et al.: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Int Med 1993, 153:973–979.

26. Bakris GL,Weir MR, DeQuattro V, et al.: Effects of an ACE inhibitor/ calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283–1289.

27. Williams ME:The diabetic patient with end stage renal disease. In Therapy in Nephrology and Hypertension. Edited by Brady HR,Wilcox CS. Philadelphia:WB Saunders; 1999:249–255.

28. U. S. Renal Data System: USRDS 1996 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. April 1996.

29. Fioretto P, Steffes MW, Sutherland DER, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.

30. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851–860.

31. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861–869.

32. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbe-sartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345(12):870–878.

 voltar